Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Laboratorios Farmaceuticos Rovi, S.A.
  6. News
  7. Summary
    ROVI   ES0157261019

LABORATORIOS FARMACEUTICOS ROVI, S.A.

(ROVI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna says COVID-19 vaccine supply outside United States to slow down

07/27/2021 | 02:21am EDT

SEOUL, July 27 (Reuters) - Moderna said on Tuesday its COVID-19 vaccine manufacturing partners outside the United States are facing delays due to laboratory testing operations that have occurred in the past few days, slowing the supply of the shot to these markets.

The vaccine maker's comments come after South Korean health officials said earlier in the day that Moderna has delayed its late-July vaccine shipment schedule for the country to August due to supply problems.

"We are currently not reserving safety stock to allow vaccines to be delivered faster, which means that we do not have stock in storage to smooth these types of shortfalls or delays," a Moderna spokesperson said.

The issue was now resolved, but the delay will lead to a short-term adjustment in the upcoming 2-4 weeks, the spokesperson said.

The shipment delay comes as the South Korean government expands its inoculation campaign to people in their 50s and workers in its vital computer chip and electronic sector.

The disruption has forced authorities to switch to the Pfizer vaccine for some vaccinations. Moderna and its manufacturing partners are working to minimize this shortfall across all impacted nations, the company said without naming the affected countries and the severity of the issue.

The supply issue is linked to the vaccine manufacturing process involving Swiss contract drugmaker Lonza and a Spain-based company, which does bottling work for the Moderna vaccine, said Jung Eun-young, head of the vaccine procurement team.

"This means the production-related issue does not only affect South Korea. Rather it is a common problem for countries that receive the volume from the manufacturing site," Jung said in a news conference.

She did not name the Spanish firm, but contract drugmaker Rovi bottles, or "fills and finishes," Moderna vaccines for markets other than the United States.

Contract drugmaker Lonza said questions on COVID-19 vaccine should be directed to Moderna. Rovi was not available for comment.

South Korea has a contract for 40 million doses of the Moderna vaccine, of which about 1.1 million have already arrived.

The country is battling a fourth wave of infections linked to the spread of the more contagious Delta variant and public complacency that has seen daily cases breach the 1,000 mark for the first time since December.

Authorities reported 1,365 new coronavirus cases for Monday.

South Korean officials said the Moderna vaccines scheduled to arrive in August remained on schedule, adding that a detailed shipment plan would be made public once finalised.

Shares of the drugmaker fell 3.7% to $323.5 in morning trade. (Reporting by Sangmi Cha; Additional reporting by Inti Landauro in Madrid, Brenna Hughes Neghaiwi in Zurich and Manas Mishra in Bengaluru; Editing by Miyoung Kim, Lincoln Feast, Joe Bavier and Arun Koyyur)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
LABORATORIOS FARMACEUTICOS ROVI, S.A. 0.88% 57.2 Delayed Quote.50.92%
LONZA GROUP AG -2.94% 752.8 Delayed Quote.32.35%
MODERNA, INC. -2.41% 430.05 Delayed Quote.311.65%
All news about LABORATORIOS FARMACEUTICOS ROVI, S.A.
09/01Moderna, Takeda Plan Recall of Suspended COVID-19 Shots in Japan Amid Contami..
MT
09/01LABORATORIOS FARMACEUTICOS ROVI S A : ROVI informs about the joint statement fro..
PU
08/30ALERT : New entry in the European portfolio
08/30What we know about Japan's contaminated Moderna COVID-19 vaccines
RE
08/30What we know about Japan's contaminated Moderna COVID-19 vaccine supplies
RE
08/30Japan's Moderna vaccine contamination woes widen as regions put holds on more..
RE
08/29LABORATORIOS FARMACEUTICOS ROVI S A : Moderna's COVID-19 Vaccine Manufacturer Ro..
MT
08/29Japan's Gunma prefecture reports contaminant in Moderna COVID-19 vaccine
RE
08/29LABORATORIOS FARMACEUTICOS ROVI S A : ROVI informs on the evolution of the inves..
PU
08/27Equities Advance Midday as Fed Chief Offers No Timeline for Tapering of Asset..
MT
More news
Financials
Sales 2021 570 M 668 M 668 M
Net income 2021 103 M 120 M 120 M
Net cash 2021 40,8 M 47,9 M 47,9 M
P/E ratio 2021 29,6x
Yield 2021 1,05%
Capitalization 3 207 M 3 765 M 3 760 M
EV / Sales 2021 5,56x
EV / Sales 2022 4,42x
Nbr of Employees 1 499
Free-Float 33,6%
Chart LABORATORIOS FARMACEUTICOS ROVI, S.A.
Duration : Period :
Laboratorios Farmaceuticos Rovi, S.A. Technical Analysis Chart | ROVI | ES0157261019 | MarketScreener
Technical analysis trends LABORATORIOS FARMACEUTICOS ROVI, S.A.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 57,20 €
Average target price 65,18 €
Spread / Average Target 14,0%
EPS Revisions
Managers and Directors
Juan López-Belmonte Encina Chairman, President & Chief Executive Officer
Javier López-Belmonte Encina First Deputy Chairman & Chief Financial Officer
Ibón Gutierro Adúriz Manager-Research & Development
José Fernando de Almansa Moreno-Barreda Independent Director
Fátima Báñez García Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LABORATORIOS FARMACEUTICOS ROVI, S.A.50.92%3 740
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.19.23%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456